SecBot SecBot
8-K ·Filed Jul 30, 2026

TEM

Tempus AI, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-326083
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong beat, first GAAP profitable quarter, raised guidance, and accelerating operational metrics (Oncology volume, MRD, Insights) are clear positives. The ~$1.5B Personalis acquisition adds a leading MRD technology but introduces integration risk and near-term dilution. Monitor the Q3 2026 call for updates on Personalis deal closure (expected late Q4 2026/early 2027) and any changes to the ~$65M Adjusted EBITDA guidance.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$43.87
T+0 close · Jul 30, 2026 · via day close
Latest settled
+53.09%
T+60 · $67.16
Vs SPY
+50.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $43.87entry
  2. T+1 · 4mo ago +4.97%α +3.54% · $46.05
  3. T+5 · 3mo ago +18.65%α +15.13% · $52.05
  4. T+20 · 3mo ago +45.98%α +42.99% · $64.04
  5. T+60 · 22d ago +53.09%α +50.63% · $67.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tempus AI reported Q2 2026 revenue of $382.5M (+22% YoY), beating consensus of $379.5M, and a non-GAAP net loss per share of -$0.04, beating the consensus estimate of -$0.15. The company achieved its first GAAP net income quarter ($5.6M), generated positive Adjusted EBITDA of $8.0M, and raised full-year revenue guidance to $1.595-$1.605B. The quarter was highlighted by strong operational metrics including 31% oncology volume growth, 36% Insights revenue growth, and ~$200M in new Data & Applications bookings, alongside the announced acquisition of Personalis for ~$1.5B.

Key Financial Metrics

EPS
−$0.04
est −$0.15 · +73.3%
Revenue
$382.5M
est $379.5M · +0.8% · +22.0% YoY
Rating
strong beat
Guidance
$1.595B-$1.605B
raised
Gross Margin
64.4%

Key Facts

  • Total revenue of $382.5M, up 22% YoY, beating consensus of $379.5M.
  • Non-GAAP net loss per share of -$0.04, beating consensus estimate of -$0.15 (73.6% beat).
  • First GAAP net income quarter of $5.6M, compared to a net loss of -$42.8M in Q2 2025.
  • Adjusted EBITDA of $8.0M, compared to -$5.6M in Q2 2025.
  • Raised full-year 2026 revenue guidance to $1.595-$1.605 billion (~25% annual growth).
  • Oncology volume grew 31% YoY; MRD volume reached 9,000 tests (up from 6,500 last quarter).
  • Data Licensing & Modeling (Insights) revenue grew 36% YoY; signed ~$200M in new Data & Applications licenses.
  • Announced definitive agreement to acquire Personalis for ~$1.5B enterprise value.
  • Completed a $460M offering of 0.0% convertible senior notes due 2032; cash and marketable securities of $820.7M.

Financial Impact

Revenue beat consensus by ~$3M; EPS beat by ~$0.11. Raised FY2026 revenue guidance by $5M at the midpoint. The ~$1.5B Personalis acquisition represents a significant strategic investment.

revenueepsebitdaguidancecash

Risk Factors

  • Integration risk and potential dilution from the ~$1.5B Personalis acquisition.
  • Operating cash flow remains negative (-$80.8M in H1 2026), though improving.
  • Revenue growth decelerated to 22% YoY from 36% YoY in Q1 2026, partly due to the Ambry acquisition anniversary.
  • GAAP net income was driven by $98.5M in unrealized gains on marketable securities, which is non-recurring.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Computer Programming, Data Processing, Etc.
Analyst Consensus
63% bullish (24 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-326083
Document: tem-20260730.htm0001193125-26-326083
Document: 0001193125-26-326083-index-headers.html0001193125-26-326083
Document: 0001193125-26-326083-index.html0001193125-26-326083
Document: 0001193125-26-326083.txt0001193125-26-326083
8-K Data (Synthetic)0001193125-26-326083

Track record

45 reports on TEM

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +40.92% at T+60 after the Jul 20, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 3/10 Entry $80.54 Now $64.76 −19.59% settles Feb 8
  2. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
  3. Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
  4. Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
  5. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $78.48 Now $64.76 −17.48% settles Jan 29
  6. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
  7. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
  8. Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
  9. Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
  10. Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
Showing 10 of 45

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026